New hope for unmatched bone marrow transplant patients
This article was originally published in Scrip
Only 30% of patients who need a bone marrow transplant find a matching donor within their family. Kiadis Pharma, a small Dutch biotech company, is working to improve the outcomes for these patients with its lead product, ATIR, for which it recently presented positive five-year follow-up data from a Phase I/II trial.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.